BioLargo Announces Results of 2025 Annual Stockholder Meeting
BioLargo (OTCQX:BLGO), an environmental and cleantech solutions company, announced the approval of all matters at its 2025 annual stockholder meeting. While shareholders approved a potential 10-for-1 reverse stock split, management clarified they have no immediate plans to implement it.
CEO Dennis Calvert emphasized that the company would only consider the reverse split if needed to meet minimum price requirements for uplisting to Nasdaq or NYSE. BioLargo currently meets all uplisting qualifications except for stock price, and management views this approval as strategic preparation for potential future opportunities.
BioLargo (OTCQX:BLGO), un'azienda specializzata in soluzioni ambientali e cleantech, ha annunciato l'approvazione di tutte le questioni all'assemblea annuale degli azionisti del 2025. Sebbene gli azionisti abbiano approvato un possibile reverse stock split 10 a 1, la direzione ha chiarito di non avere piani immediati per attuarlo.
Il CEO Dennis Calvert ha sottolineato che la società considererebbe il reverse split solo se necessario per soddisfare i requisiti minimi di prezzo per la quotazione su Nasdaq o NYSE. Attualmente BioLargo soddisfa tutti i criteri per l'up-listing tranne il prezzo delle azioni, e la direzione vede questa approvazione come una preparazione strategica per opportunità future.
BioLargo (OTCQX:BLGO), una empresa de soluciones ambientales y cleantech, anunció la aprobación de todos los puntos en su reunión anual de accionistas de 2025. Aunque los accionistas aprobaron una posible consolidación inversa de acciones 10 a 1, la gerencia aclaró que no tiene planes inmediatos para implementarla.
El CEO Dennis Calvert enfatizó que la compañía solo consideraría la consolidación inversa si fuera necesaria para cumplir con los requisitos mínimos de precio para la cotización en Nasdaq o NYSE. BioLargo actualmente cumple con todos los requisitos para la cotización, excepto el precio de las acciones, y la gerencia ve esta aprobación como una preparación estratégica para oportunidades futuras.
BioLargo (OTCQX:BLGO)는 환경 및 클린테크 솔루션 회사로, 2025년 연례 주주총회에서 모든 안건이 승인되었다고 발표했습니다. 주주들은 잠재적인 10대 1 역병합을 승인했으나, 경영진은 당장 이를 시행할 계획이 없다고 밝혔습니다.
CEO 데니스 캘버트는 회사가 나스닥 또는 NYSE 상장 요건을 충족하기 위해 최소 주가 요건이 필요할 경우에만 역병합을 고려할 것이라고 강조했습니다. BioLargo는 현재 주가를 제외한 모든 상장 요건을 충족하고 있으며, 경영진은 이번 승인을 향후 기회에 대비한 전략적 준비로 보고 있습니다.
BioLargo (OTCQX:BLGO), une entreprise spécialisée dans les solutions environnementales et cleantech, a annoncé l'approbation de toutes les résolutions lors de son assemblée annuelle des actionnaires 2025. Bien que les actionnaires aient approuvé une éventuelle division inversée d'actions 10 pour 1, la direction a précisé qu'elle n'a pas de plans immédiats pour la mettre en œuvre.
Le PDG Dennis Calvert a souligné que la société envisagerait la division inversée uniquement si cela s'avérait nécessaire pour répondre aux exigences minimales de prix en vue d'une cotation sur le Nasdaq ou le NYSE. BioLargo remplit actuellement tous les critères de cotation sauf le prix de l'action, et la direction voit cette approbation comme une préparation stratégique pour de futures opportunités.
BioLargo (OTCQX:BLGO), ein Unternehmen für Umwelt- und Cleantech-Lösungen, gab die Genehmigung aller Tagesordnungspunkte auf seiner Hauptversammlung 2025 bekannt. Obwohl die Aktionäre einem möglichen 10-zu-1 Reverse Stock Split zugestimmt haben, stellte das Management klar, dass keine unmittelbaren Pläne zur Umsetzung bestehen.
CEO Dennis Calvert betonte, dass das Unternehmen den Reverse Split nur in Betracht ziehen würde, wenn dies erforderlich ist, um die Mindestpreisvoraussetzungen für eine Notierung an der Nasdaq oder NYSE zu erfüllen. BioLargo erfüllt derzeit alle Voraussetzungen für ein Uplisting außer dem Aktienkurs, und das Management betrachtet diese Genehmigung als strategische Vorbereitung auf mögliche zukünftige Chancen.
- Company meets all uplisting requirements for national exchanges except stock price
- Management maintains flexibility for strategic uplisting without immediate dilution
- All matters submitted to stockholder vote were approved
- Current stock price remains below national exchange listing requirements
- Trading on OTCQX limits institutional investor access and liquidity
No immediate intention to proceed with a reverse stock split - "This vote empowers us to be ready when the time is right."
WESTMINSTER, CA / ACCESS Newswire / June 26, 2025 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, today announced that all matters submitted to a vote of the stockholders at its 2025 annual stockholder meeting were approved. Although the proposal authorizing the company's board to implement a reverse stock split in a ratio of up to 10-for-1 was approved, the board has no immediate plans to do so, instead intending to do so only in conjunction with an uplisting to Nasdaq or the New York Stock Exchange, and only if needed to meet the minimum price requirement.
BioLargo's CEO Dennis Calvert commented, "We believe BioLargo is at a pivotal moment in its journey, with momentum building across multiple fronts of our business. As we execute on our commercial strategy, we expect our stock price to increase. In such a scenario, we want to be fully prepared to take the next strategic step-uplisting to a national exchange-to expand our reach and attract institutional investors, enhance trading liquidity, and build a broader base of long-term stockholders. While we currently meet all key qualifications for uplisting except stock price, our Board of Directors believes it's prudent to have the flexibility to act decisively if market conditions align with our growth. This vote empowers us to be ready when the time is right."
BioLargo filed a Form 8-K with the U.S. Securities and Exchange Commission disclosing the voting results on January 25, 2025 (https://www.biolargo.com/sec-filings).
About BioLargo, Inc.
BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.
SOURCE: BioLargo, Inc
View the original press release on ACCESS Newswire
FAQ
What did BioLargo (BLGO) announce about reverse stock split in 2025?
What are BioLargo's requirements for uplisting to Nasdaq or NYSE?
When did BioLargo file the Form 8-K with voting results?
What was the outcome of BioLargo's 2025 annual stockholder meeting?
